Caris Life Sciences CAI Estimates

NASDAQ CAI
$24.72 -0.60 (-2.38%)
As of: Sep 4, 2026 · 10:50 AM EDT
Analyst Estimates

Caris Life Sciences, Inc. Revenue Estimates

Periods 24
Next Period Q2 26
Consensus 251.80 M

Analysts expect Caris Life Sciences, Inc. to report revenue of 251.80 M for Q2 26, against a range of 228.57 M to 275.04 M. The most recent reported quarter, Q1 26, came in at 216.17 M, a 7.6% beat against the 200.87 M consensus.

Metric Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 120.91 M181.40 M216.83 M292.89 M216.17 M--------
High Estimate -153.25 M195.46 M258.51 M218.80 M275.04 M298.13 M279.55 M299.68 M326.09 M338.05 M404.07 M315.08 M
Low Estimate -131.41 M175.49 M237.35 M182.94 M228.57 M256.39 M257.77 M259.73 M277.56 M314.52 M336.19 M281.30 M
Consensus Estimate -142.33 M185.48 M247.93 M200.87 M251.80 M277.26 M268.66 M279.70 M301.82 M326.29 M370.13 M298.19 M
Analyst Estimates

Caris Life Sciences, Inc. Earnings Per Share (EPS) Estimates

Periods 24
Next Period Q2 26
Consensus 0.01

Analysts expect Caris Life Sciences, Inc. to report earnings per share of 0.01 for Q2 26, against a range of 0.01 to 0.01. The most recent reported quarter, Q1 26, came in at 0.00, a 100.0% beat against the -0.02 consensus.

Metric Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -0.35-7.970.080.280.00--------
High Estimate --0.20-0.160.05-0.020.010.040.080.040.231.690.74-0.75
Low Estimate --0.22-0.180.05-0.020.010.040.060.040.191.590.68-0.83
Consensus Estimate --0.21-0.170.05-0.020.010.040.070.040.211.640.71-0.79